“…CDFs allow an examination of how trials with the fastest RTs differ from those with slower RTs which would be considered unrepresentative of the StartReact effect, whilst avoiding the pitfalls of relying on SCM activity as an indicator of StartReact mechanisms which have been outlined previously (Marinovic & Tresilian, 2016). We re-analysed data from seven studies (Castellote & Kofler, 2018;Honeycutt, Kharouta, & Perreault, 2013;Marinovic, de Rugy, Riek, & Tresilian, 2014;Marinovic, Milford, Carroll, & Riek, 2015;Ossanna, Zong, Ravichandran, & Honeycutt, 2019; which have investigated differences in response times across trials in the presence and absence of SCM activity. We used our method to evaluate the utility of separating trials on the basis of SCM activity by examining the distribution of SCM activity across the spectrum of RTs and evaluating the relationship between RT and the presence of SCM activity.…”